Schizophrenic patients who are treated with antipsychotics, especially second generation antipsychotics, such as clozapine and olanzapine, manifest an increase in cholesterol and triglycerides as well as other changes associated with diabetes or the metabolic syndrome. Previous studies have shown that polymorphisms in several genes that regulate lipid metabolism can influence the levels of these lipids and response to drug treatment. We have investigated in an exploratory study whether polymorphisms in the apolipoprotein C-III (ApoC3), apolipoprotein A-V gene (ApoA5) and lipoprotein lipase genes influence differential lipid response to treatment with three second generation antipsychotics-olanzapine, clozapine and risperidone-or treatment with a first generation antipsychotic. A total of 189 patients with schizophrenia or schizoaffective disorder who were being treated with a single antipsychotic were studied in a cross-sectional study design in which fasting serum cholesterol and triglycerides and selected single-nucleotide polymorphosms (SNPs) in the three lipid metabolism genes were assessed. The treatment with antipsychotic monotherapy makes drug haplotype ascertainment less complex. Our analyses showed several nominally significant drug Â gene and drug Â haplotype interactions. The rarer C allele or the ApoA5_1131 (T/C) SNP was associated with higher cholesterol levels in patients treated with first generation antipsychotics and lower cholesterol levels in patients treated with olanzapine or clozapine. The rarer C allele of the ApoA5_SW19 (G/C) SNP was associated with higher cholesterol in risperidone-treated patients. An ApoA5 CG haplotype was associated with decreased cholesterol in olanzapine-or clozapine-treated patients and higher cholesterol in patients treated with first generation antipsychotics. The presence of the rarer T allele of the ApoC3_1100 (C/T) SNP or the presence of the ApoC3 TG haplotype was associated with decreased triglyceride levels in patients treated with olanzapine or clozapine and a nonsignificant trend for increased triglycerides in patients treated with first generation antipsychotics. The presence of the ApoC3 CC haplotype was associated with increased triglycerides in patients treated with olanzapine or clozapine. The overall magnitude of the effects was not large. These results provide a potential initial step toward a pharmacogenetic approach to selection of antipsychotic treatment which may help minimize the side effect of increases in serum lipids.
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Introduction
Second generation antipsychotics, which are increasingly widely used as first line treatment for both schizophrenia and bipolar disorder, are associated with metabolic abnormalities which may increase the risk of diabetes and atherosclerotic cardiovascular disease. 1 Several studies have noted increases in serum lipids after treatment with some conventional and second generation antipsychotics, with an increase reported for both triglycerides and cholesterol. 2 Our previously published study of patients treated with either a conventional or one of the three second generation antipsychotics reported a significant increase in fasting triglycerides in patients treated with clozapine or olanzapine, compared to risperidone, and a strong trend for similar increase in serum cholesterol. 3 Numerous studies indicate that levels of triglycerides and cholesterol in the blood are influenced by variations in genes which control or influence lipid metabolism. 4, 5 Among the many candidate genes are the apolipoprotein C-III (ApoC3), apolipoprotein A-V gene (ApoA5) and lipoprotein lipase (LPL) genes. (Table 1) . Polymorphisms in these genes have been shown to influence serum or plasma triglyceride levels [6] [7] [8] and some of these variations have also been shown to influence cholesterol and other serum lipid parameters. 9 Several studies have revealed pharmacogenetic interactions of polymorphisms in lipid genes and metabolic response to statin drug treatment (for a review see Knoblauch et al. 10 ; Schmitz et al. 11 ). To our knowledge, no studies have investigated whether there are differential pharmacogenetic interactions between polymorphisms in genes that influence lipid levels and the effects of antipsychotic drugs on triglycerides and cholesterol in patients treated with these medications. This report presents an initial attempt to begin to address this question in an exploratory study with a cross-sectional study design. We explored whether one or more single-nucleotide polymorphosms (SNPs) or haplotypes, in a few candidate genes which have been previously shown to influence lipid metabolism (Table 1) , would affect the levels of triglycerides or cholesterol in schizophrenic patients treated with antipsychotic drugs and whether there would be differential genetic effects with the different types of antipsychotic medications. This was an exploratory hypothesis generating study and there were no defined a priori hypotheses for differential drug Â gene interaction effects of a specific SNP or haplotype to be tested.
Results
The characteristics of our sample (Table 2) shows that there were no significant (Po0.05) differences in age, sex, ethnicity or basal metabolic index (BMI) among the four drug groups (additional characteristics of the overall slightly larger sample used in the original study (n ¼ 210, including 21 patients for whom we did not obtain genetic samples) were presented in our previous publication 3 ). Patients treated with clozapine or Lipid genes and antipsychotic metabolic effects RC Smith et al olanzapine had significantly higher triglyceride levels and tended to have higher cholesterol levels, consistent with our previously reported results. All SNPs were in Hardy-Weinberg equilibrium (HWE). Table 3 presents the allele and genotype frequencies in the sample used in these analyses. Minor allele frequencies for all loci examined were similar to those observed in previous large-scale association studies in normal population samples. All minor allele frequencies were 10% or higher except for the ApoA5_S_w19 and LPLS44X SNPs where the minor allele frequencies were 7%. The two ApoA5 SNPs were in strong linkage disequilibrium (LD) (D 0 ¼ 1); the two ApoC3 SNPs were in moderately high LD (D 0 ¼ 0.86). Table 4 presents the haplotype frequencies.
In this sample, none of the SNP variations alone had a significant main effect on serum cholesterol or triglycerides, except for the ApoA5_1131 SNP where the rarer (C) allele was associated with lower serum triglycerides in both a dominant (TT vs (TC or CC), F ¼ 4.438, df ¼ 1185 P ¼ 0.036) or additive (TT vs TC vs CC, F ¼ 3.846, df ¼ 2184 P ¼ 0.023) analysis. However, there were significant drug Â gene interactions for several SNPs on either serum cholesterol or triglycerides, and some drug Â haplotype interactions (see Table 5 ; additional Supplementary Tables 6 and 7 online show results of all analyses). Only one SNP drug Â gene interaction for cholesterol levels (ApoA5_1131), and one haplotype Â gene interaction (ApoA5 CG haplotype) was still significant after Bonferroni correction (with a ¼ 05). Figure 1 shows two drug Â SNP effects. For serum cholesterol (Figure 1a) , the ApoA51131 SNP showed a significant drug Â SNP interaction in a dominant analysis (drug Â SNP (TT vs (TC or CC)), interaction effect, F ¼ 6.830, df ¼ 2,181 P ¼ 0.011), with the C allele associated with lower cholesterol levels in patients taking second generation antipsychotics and with higher cholesterol levels in patients taking first generation antipsychotics.
For serum triglycerides (Figure 1b) , the ApoC31100 SNP interacted in a complex way with antipsychotic effects (drug Â SNP (CC vs CT vs TT), interaction effect, F ¼ 2.463, df ¼ 4,179, P ¼ 0.044). For patients treated with clozapine or olanzapine, the TT genotype was associated with lower triglycerides, whereas the T allele was associated with ApoC3_CC (ApoC3_1100-C/ApoC3_3238-C) 0.92 0.08 For this analysis, the rarer SNP variant in comparison, or rarer haplotype (or haplotype combination) present is small number in total sample, that is, np5; *F significant (at a ¼ 0.05) with Bonferroni correction with number of ANOVAs for SNP or haplotype analyses considered separately for each dependent variable mean (a) cholesterol or (b) mean triglyceride. Cases haplotypes both carried ¼ cases without two haplotypes present vs cases who do not have the two haplotypes present. Only those drug Â gene interactions for which the ANOVAs showed either F with P at trend level (that is, slightly higher triglycerides slightly in patients treated with first generation antipsychotics, although this latter effect was not statistically significant. The differences in mean triglyceride levels produced by the drug Â SNP interaction effects were quantitatively smaller than the mean cholesterol differences. There was a nonsignificant trend for ApoC33238 SNP to show a drug Â gene interaction in a dominant analysis (drug Â SNP (CC vs (CG or GG)) interaction effect F ¼ 2.364, df ¼ 2,181 P ¼ 0.088) with the rarer G allele tending to be associated with lower triglyceride levels in only the clozapine-or olanzapine-treated patients (P ¼ 0.081).
Some haplotypes showed interactive effects with drugs, but these were not consistently more pronounced or more statistically significant than the individual SNPs discussed above (see Figure 2 for examples). For cholesterol (Figure 2a) , the ApoA5 CG haplotype showed a drug Â haplotype interaction (F ¼ 6.657, df ¼ 2,182, P ¼ 0.002); patients with the haplotype present showed higher cholesterol (mean difference þ 39.7 mg/dl) if they were being treated with first generation antipsychotics (t-test P ¼ 0.022) and slightly lower cholesterol (mean difference À18.6 mg/dl) if they were being treated with olanzapine or clozapine (t-test P ¼ 0.049). When we classified the small number of subjects (n ¼ 7) with both the ApoC3 TG and TC haplotypes vs those who did not have these two haplotypes, there was a significant drug Â haplotype interaction (F ¼ 4.003, df ¼ 2,182, P ¼ 0.02) with positive cases treated with conventional antipsychotics having higher cholesterol than negative cases (mean difference þ 50.7 mg/dl, t-test P ¼ 0.020) and positive cases treated with olanzapine or clozapine showing a trend for slightly lower cholesterol than negative cases (mean difference À35.6 mg/dl, t-test P ¼ 0.097).
For triglycerides, the ApoC3 TG haplotype showed a trend for a drug Â haplotype interaction (F ¼ 2.740 DF ¼ 2,182, P ¼ 0.067). The olanzapine-and clozapine-treated patients with the haplotype showed slightly decreased triglycerides compared to noncarriers (mean log 10 difference Â 100 ¼ À9.9 mg/dl; t-test P ¼ 0.048). The ApoC3 CC haplotype (Figure 2b) showed a trend for a drug Â haplotype interaction on triglyceride levels (F ¼ 2.390 df ¼ 2,182, P ¼ 0.094) with the olanzapine and clozapine-treated patients with the haplotype present having higher triglyceride levels than the patients with haplotype absent (mean log 10 difference Â 100 ¼ þ 17.3 mg/dl, t-test P ¼ 0.027). For the small number of patients (N ¼ 7) who had both the ApoC3 TG and TC haplotypes, there was a trend for a drug Â haplotype interaction (F ¼ 2861, df ¼ 2182, P ¼ 0.060). The patients treated with olanzapine or clozapine who were positive for the two haplotypes showed lower triglycerides than the negative cases (mean log 10 difference Â 100 ¼ À28.5 mg/dl; t-test P ¼ 0.023), whereas in the other drug groups the positive haplotype cases showed either no change or a nonsignificant trend for higher triglycerides.
The length of drug treatment with the current antipsychotic in this sample did not strongly influence the significance of the drug Â gene interaction effects. In this sample, the correlation between months of treatments with current antipsychotic and cholesterol or triglyceride levels at time of our evaluation was small (Pearson's r all o0.20) and not statistically significant for any of the four antipsychotics or drug classes. When we performed additional analysis of variances (ANOVAs) for the drug Â gene or haplotype Â gene effects in subsamples of patients who had been treated with the antipsychotic for greater than 3 or 5 months, the statistical significance or effect size of the drug Â gene interactions were not generally increased, although a few analysis showed very slightly increased statistical significance at the longer treatment times. Statistical analyses did not show study site effect on the drug Â gene interaction effects we examined.
Discussion
Increases in serum lipids are increasingly recognized as important side effects of antipsychotic drugs, especially the second generation antipsychotics olanzapine and clozapine. These changes are putatively related to increased risk of diabetes and atherosclerotic cardiovascular disease. Although recent studies have suggested that olanzapine and clozapine may be more effective than other antipsychotics in treatment of schizophrenia, 12,13 especially partially responsive or treatment-resistant schizophrenia, [14] [15] [16] the effects of these two drugs on weight gain and their metabolic effects on glucose and lipids may limit their overall utility because of risk/benefit ratios. If we could identify characteristics of patients who would be more or less likely to develop increases in lipids with specific types of antipsychotics, this could help inform clinicians' evaluation of risk/benefit propensity and aid in drug selection. The influence of variation in lipid genes on differential drug response to triglycerides and cholesterol, which we have investigated in this report, is one potential avenue to explore in trying to increase knowledge about these predictive patient characteristics. This is the first study to show differential associations of allelic variations in the ApoC3 and ApoA5 genes, which encode proteins that are involved in lipid metabolism, with the effect of first and second generation antipsychotics on cholesterol and triglyceride levels. The treatment with antipsychotic monotherapy in this sample makes drug phenotype assessment clearer and less complex. For some SNPs, the minor allele was associated with lower serum cholesterol or triglyceride levels among patients treated with olanzapine or clozapine and higher levels of these lipids in patients treated with first generation antipsychotics. An ApoA5 CG haplotype had a similar effect. The presence of the W (minor) allele of the ApoA5_S19W SNP was associated with increased serum cholesterol in patients treated with risperidone. Although we selected SNPs in genes for which effects on triglyceride levels had been primarily demonstrated, only one of the allelic variations (ApoA5_1131) showed a significant overall effect on serum triglycerides. In the drug Â gene interactions, there were stronger and more numerous statistically significant effects on serum cholesterol than serum triglycerides. Overall, the differential effects of these allelic variations were fairly modest, not more than about 50 mg/dl for cholesterol and not more than about 30 mg/dl for serum triglycerides, and effect sizes in the drug Â gene interactions in the ANOVAs were small. However, since schizophrenic patients are frequently treated with antipsychotics over several decades, the effects of these relatively small differences in drug effects on cholesterol or triglycerides may be of more clinical significance over many years of drug treatment. Furthermore, because of the number of statistical tests performed, it is possible that some of our statistically significant results from ANOVAs could have arisen from chance occurrence, although two of the drug Â gene or haplotype interactions were still significant after Bonferroni correction (a ¼ 0.05) for multiple tests. In an exploratory study like this, it may be useful to consider statistical significance at both traditional and corrected significance level testing.
It is important to acknowledge some other potential weaknesses in the design of this initial study. Our data arose from a cross-sectional study of patients treated with single antipsychotics for varying lengths of time (mean length of treatment 6-8 months). It is possible that prior treatment with other antipsychotics or the concomitant medications the patients were taking at the time (see Smith et al. 3 for details) could have influenced results. A longitudinal design, with random assignment to two or more antipsychotic drugs might yield more clearly interpretable results. Furthermore, this was an ethnically mixed sample of Caucasians, Blacks and nonblack Hispanics. Although our analysis showed no significant effects of ethnicity on allelic or genotype distribution among the ethnic groups, it is possible that a much larger sample would have allowed us to look for stronger differential drug Â gene interactions in specific ethnic groups. Although the minor allele frequencies in this sample are similar to those in several other published studies with these SNPs, the relatively low minor allele frequencies may reduce the power and may require larger sample sizes to detect significant effects.
We do not have a mechanistic explanation of why several of the SNP or haplotype variations have differential effects on cholesterol and triglyceride levels in patients treated with olanzpaine and clozapine compared to those treated with conventional (first generation) antipsychotics. Both olanzapine and clozapine are thought to have higher affinity in vitro to various subclasses of serotonin receptors (especially serotonin 1A , 2C ) and cholinergic receptors than conventional antipsychotics. [17] [18] [19] Olanzapine and clozapine may also stimulate weight gain through activation of hypothalamic AMP increase which may be mediated through actions on histamine H1 receptors. 20 Whether any of these receptor differences are related to the differential effects of the SNPs, we examined on cholesterol and triglycerides in olanzapine and clozapine as compared to those treated with conventional antipsychotics may merit further investigation.
It is possible that variations in other SNPs in both the genes we studied and in other genes which have been shown to influence lipid metabolism could provide additional or stronger markers for differential gene effects of antipsychotic tendencies to produce lipid increases. Other identified SNPs in the ApoC3 (À482, À2854), ApoA5 (À3, 56, IVS3 þ 476,1259) and LPL (N291S, D9N, V108v, HindIII) genes have been shown to influence lipid metabolism and/ or cardiovascular risk outcomes in some studies. 7, [21] [22] [23] [24] Furthermore, other genes such as the ApoE, ApoA1, ApoB, hepatic lipase and PPAR genes have been investigated for their association with lipid levels and/or cardiovascular disease outcomes. 4, 10, [25] [26] [27] Since weight gain and BMI are significantly correlated with serum triglycerides and cholesterol levels, it is possible that genetic variants which may influence the extent of weight gain during treatment with antipsychotics, such as the polymorphisms in the 5-HT2C receptor (À759 T/C), 28, 29 polymorphisms of the leptin gene, 28, 30 and polymorphisms in the a2A receptor (À1291 C/G) 31 may also be related to deferential drug Â gene effects on serum lipids. In this initial study, we could only investigate a few polymorphisms which previous studies suggested may have significant effects on plasma or serum triglycerides or cholesterol; we also chose SNPs with a minor allele frequency of at least 10% in some prior studies. Our statistically significant findings had modest effect sizes and explained only a small percent of the variance. If additional effects from variation in SNPs in other genes increased the overall percent of variance explained, this might increase the clinical utility of a pharmacogenetic approach in antipsychotic drug selection based on prediction of these types of side effects.
Materials and methods

Patients
Details of the sample and study design are described in detail in our previous publication. 3 In brief, this was a crosssectional study of fasting glucose and lipid metabolism in patients with schizophrenia or schizoaffective disorder diagnosed according to DSM-IV, who had been treated with a single antipsychotic agent (clozapine, olanzapine, risperidone or a first generation antipsychotic) for at least 1 month and were hospitalized at one of the three tertiary care public hospitals in the United States. Patients gave written informed consent for participation in the study, after the purposes and procedures were explained. The protocol and consent forms were approved by each Institutional Review Board.
Metabolic assessment procedures and assays
On two mornings before breakfast, patients had blood samples drawn for analysis of serum glucose and lipids including serum cholesterol and triglycerides. Values obtained on the two days were averaged and the mean values were used in the statistical analyses described below, except in the few cases where values from only 1 day were available for a specific determination because of laboratory problems. Assays for cholesterol and triglycerides were carried out at the regional clinical chemistry laboratory of Nathan Kline Institute; serum cholesterol and triglycerides were determined by enzymatic procedures using Roche/ Hitachi Kits.
SNP selection and genotyping
In this initial study, we were able to examine a few SNPs in putatively relevant genes. SNPs were selected for genotyping on the basis of prior information regarding their functional role in lipid and triglyceride metabolism. Details are shown in Table 1 . The 447 serine stop codon (Ser447X) is a common variant located in exon 9 of the LPL gene that produces a truncated protein lacking 2 amino acids at the carboxy terminus. This variant has been found to associate with elevated secretion of LPL mass without affecting lipolytic activity. 28 The 447X form has been previously associated with lower TG levels and higher high-density lipoprotein levels in population samples. 8, [32] [33] [34] ApoC3 gene variations have been associated with elevated triglyceride levels in a number of studies. Two exonic polymorphic sites, the exon 4 3238C4G and the exon 3 1100C4T substitutions, previously found to be associated with increased TG levels in healthy adults were genotyped in the current study. 7, 35 Several polymorphisms in the ApoA5 gene have been previously found to associate with plasma triglyceride levels in healthy population. 6 For the current study, two polymorphisms were analyzed, the exon 2 S19W (56C4G) and the promoter À1131T4C sites. Both were associated with small but significant elevations in plasma triglycerides levels in a number of studies. 6 For DNA extraction, 30 cc of blood were collected in ethylene diamine tetra acetic acid tubes. Genomic DNA was extracted from whole blood using the Puregene DNA purification system (Gentra Systems, Minneapolis, MN, USA). Genotyping of SNPs was performed by the 5 0 exonuclease method using fluorogenic allele-specific probes and commercially available probes and primers (Assays-byDemand, Applied Biosystems, Forster City, CA, USA) ( Table 1 ). The amplification reactions were performed in 20 ml volume, including 20 ng DNA, 10 ml of PCR Master Mix (Applied Biosystems), containing AmpliTaq Gold DNA Polymerase, dNTPs, Gold Buffer and MgCl 2 , 900 nM of each forward and reverse primer, and 200 nM of each reporter and quencher probe Assays on-Demand (Applied Biosystems), in each reaction well. Amplification was performed in a PCR System 7500 (Applied Biosystems). Amplification conditions were 951C for 15 s, 601C for 1 min, 40 cycles, after one initial step at 951C, for 10 min, which was set to activate the AmpliTaq Gold polymerase (ABI In Vivio Scribe, San Diego, CA, USA). Allele-specific signals were distinguished by measuring end point 6-FAM or VIC fluorescence intensities and genotypes were generated using Sequence Detection System Software Version 1.2.2 (Applied Biosystems).
Statistical analysis
Because of substantial deviation from normality, triglyceride values were log 10 transformed and the log transformed values, which approximated a normal distribution, were used in the statistical analyses. Statistical analyses were performed with SPSS 12.0 and Systat 11 using general linear model ANOVA with drug group and SNP or haplotype as factors and BMI as covariate. LD between SNPs in the same gene was determined with Haploview version 3.12.
Haploview was also used to detect significant departure from HWE (Po0.05), which was not found for any of the SNPs. Individual haplotype estimations from the population genotype data were obtained using the program, PHASE version 2 (see electronic database information-Stephens 2001, 2003).
Drug groups were defined as olanzapine þ clozapine, risperidone and conventional (first generation) antipsychotics. Olanzapine and clozapine were combined, because our prior research and that of others has shown that these drugs have a fairly similar effect on weight, cholesterol and triglycerides (see review by Newcomer 1 ). We tested for main effects of drug and SNP or haplotype on cholesterol and triglyceride levels and drug Â SNP or drug Â haplotype interactions, the interactions being our primary interest in this paper. The analyses were performed for dominant (that is, 11 vs 12 þ 22 genotypes) and additive effects (that is, 11 vs 12 vs 22). BMI was included as covariate, because it was significantly correlated with both triglyceride (r ¼ 0.44, P ¼ 0.001) and cholesterol (r ¼ 0.20, P ¼ 0.007) levels; the BMI covariate had an independent statistically significant effect (Po0.01) in all ANOVAs. Ethnicity was not included as a separate factor in the ANOVAs, because it did not interact with drug effects on cholesterol or triglycerides and there were no ethnic differences in the allele frequency of the SNPs. For those ANOVAs where there was a statistically significant (Po0.05) effect or trend (Po0.10) for drug Â gene interaction, post-hoc t-tests were used to test for a difference in cholesterol or triglyceride levels among the genotypes. For categorical variables, w 2 or Fisher's exact tests were used. Statistical significance is presented at traditional significance levels, and was also evaluated for Bonferroni corrected significance levels (a ¼ 0.05). Bonferroni significance levels were evaluated separately for the ANOVAs for cholesterol for SNPs (N ¼ 9 tests), cholesterol for haplotypes (N ¼ 12 tests), triglyceride for SNPs (N ¼ 9 tests) and triglycerides for haplotypes (N ¼ 12 tests). Effect size for the individual ANOVAs was expressed as partial eta-squared from the SPSS analysis.
Electronic database information
Ensembl Genome Browser: www.ensembl.org; Haploview, version 3.12: www.broad.mit.edu/mpg/haploview; PHASE version 2.0: http://www.stat.washington.edu/stephens/.
